Inventor · disambiguated record
Thomas Dudler
Also filed as: DUDLER THOMAS · DUDLER THOMAS A
24 granted patents·40 pending applications·183 citations·filing 2010–2024
95Inventor score
Top patents by PatentIndex Score
64 records- 0196US9644035B2Methods for treating conditions associated with MASP-2 dependent complement activationOMEROS CORP·Filed 2013·Granted May 9, 2017·18 cites·15 claims
- 0296US9475885B2Compositions for inhibiting MASP-2 dependent complement activationOMEROS CORP·Filed 2015·Granted Oct 25, 2016·15 cites·31 claims
- 0396US8652477B2Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activationSCHWAEBLE HANS-WILHELM·Filed 2010·Granted Feb 18, 2014·61 cites·18 claims
- 0495US8840893B2Methods for treating conditions associated with MASP-2 dependent complement activationSCHWAEBLE HANS-WILHELM·Filed 2011·Granted Sep 23, 2014·36 cites·12 claims
- 0594US8951522B2Methods for treating conditions associated with MASP-2 dependent complement activationDEMOPULOS GREGORY A·Filed 2012·Granted Feb 10, 2015·19 cites·14 claims
- 0692US10745274B1Nucleic acids encoding antibodies specifically binding to MASP-3OMEROS CORP·Filed 2020·Granted Aug 18, 2020·2 cites·13 claims
- 0791US9011860B2Compositions for inhibiting MASP-2 dependent complement activationDUDLER THOMAS·Filed 2012·Granted Apr 21, 2015·20 cites·24 claims
- 0889US12091468B2Therapeutic antibodies that bind to the serine protease domain of MASP-2 and uses thereofOMEROS CORP·Filed 2023·Granted Sep 17, 2024·1 cites·18 claims
- 0988US11883493B2Antibodies specifically binding to MASP-3 for the treatment of various diseases and disordersOMEROS CORP·Filed 2021·Granted Jan 30, 2024·1 cites·17 claims
- 1088US10870708B2Methods for inhibiting angiogenesis in a subject in need thereofOMEROS CORP·Filed 2017·Granted Dec 22, 2020·3 cites·3 claims
- 1188US2025059299A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationOMEROS CORP·Filed 2024·Application pending·0 cites
- 1287US11027015B2Antibodies specifically binding to MASP-3 for the treatment of various diseases and disordersOMEROS CORP·Filed 2020·Granted Jun 8, 2021·1 cites·19 claims
- 1387US10059776B2Methods for treating conditions associated with MASP-2 dependent complement activationOMEROS CORP·Filed 2017·Granted Aug 28, 2018·2 cites·14 claims
- 1487US2024342278A1Antibodies specifically binding to masp-3 for the treatment of various diseases and disordersOMEROS CORP·Filed 2023·Application pending·0 cites
- 1586US2024228665A1Methods for treating conditions associated with masp-2 dependent complement activationOMEROS CORP·Filed 2023·Application pending·0 cites
- 1686US2024254257A1Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Various Diseases and DisordersOMEROS CORP·Filed 2023·Application pending·0 cites
- 1785US11981749B2Methods for treating conditions associated with MASP-2 dependent complement activationOMEROS CORP·Filed 2020·Granted May 14, 2024·1 cites·8 claims
- 1885US11525011B2Methods of inhibiting MASP-2-dependent complement activation in a subject suffering from catastrophic antiphospholipid syndromeOMEROS CORP·Filed 2019·Granted Dec 13, 2022·1 cites·12 claims
- 1985US2024076409A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationOMEROS CORP·Filed 2023·Application pending·0 cites
- 2083US2024092938A1Compositions for inhibiting masp-2 dependent complement activationOMEROS CORP·Filed 2023·Application pending·0 cites
- 2182US10639369B2Antibodies specifically binding to MASP-3 for the treatment of various diseases and disordersOMEROS CORP·Filed 2017·Granted May 5, 2020·2 cites·30 claims
- 2281US11884742B2Methods for treating conditions associated with MASP-2 dependent complement activationOMEROS CORP·Filed 2019·Granted Jan 30, 2024·0 cites·14 claims
- 2381US2024352152A1Methods for inhibiting angiogenesis in a subject in need thereofOMEROS CORP·Filed 2024·Application pending·0 cites
- 2480US2024293465A1Methods for Treating and/or Preventing Graft-Versus-Host Disease and/or Diffuse Alveolar Hemorrhage and/or Veno-Occlusive Disease Associated with Hematopoietic Stem Cell TransplantOMEROS CORP·Filed 2023·Application pending·0 cites
- 2579US2025092157A1Methods for inhibiting fibrosis in a subject in need thereofUNIV LEICESTER·Filed 2024·Application pending·0 cites
- 2678US2024343830A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationOMEROS CORP·Filed 2024·Application pending·0 cites
- 2778US2022259325A1Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Various Diseases and DisordersOMEROS CORP·Filed 2021·Application pending·0 cites
- 2877US2022089781A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationOMEROS CORP·Filed 2021·Application pending·0 cites
- 2976US2022002439A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationOMEROS CORP·Filed 2021·Application pending·0 cites
- 3076US2023212314A1Compositions and Methods of Inhibiting MASP-2 for the Treatment of Various Thrombotic Diseases and DisordersOMEROS CORP·Filed 2022·Application pending·0 cites
- 3176US2024424091A1Methods for Inhibiting Fibrosis in a Subject in Need ThereofUNIV LEICESTER·Filed 2024·Application pending·0 cites
- 3276US2024218080A1Methods for treating and/or preventing idiopathic pneumonia syndrome (ips) and/or capillary leak syndrome (cls) and/or engraftment syndrome (es) and/or fluid overload (fo) associated with hematopoietic stem cell transplantOMEROS CORP·Filed 2024·Application pending·0 cites
- 3376US2024124611A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationOMEROS CORP·Filed 2022·Application pending·0 cites
- 3475US11896621B2Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplantOMEROS CORP·Filed 2021·Granted Feb 13, 2024·0 cites·10 claims
- 3573US11613589B2Compositions for inhibiting MASP-2 dependent complement activationOMEROS CORP·Filed 2020·Granted Mar 28, 2023·0 cites·13 claims
- 3673US2015166676A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationOMEROS CORP·Filed 2014·Application pending·0 cites
- 3772US11981748B2Methods for inhibiting angiogenesis in a subject in need thereofOMEROS CORP·Filed 2020·Granted May 14, 2024·0 cites·2 claims
- 3871US2021054098A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationOMEROS CORP·Filed 2020·Application pending·0 cites
- 3970US10683367B2Compositions for inhibiting MASP-2 dependent complement activationOMEROS CORP·Filed 2018·Granted Jun 16, 2020·0 cites·33 claims
- 4070US2020048366A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationOMEROS CORP·Filed 2019·Application pending·0 cites
- 4168US11013772B2Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplantOMEROS CORP·Filed 2018·Granted May 25, 2021·0 cites·13 claims
- 4268US2019016824A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationOMEROS CORP·Filed 2018·Application pending·0 cites
- 4367US12005117B2Methods for inhibiting fibrosis in a subject in need thereofUNIV LEICESTER·Filed 2020·Granted Jun 11, 2024·0 cites·13 claims
- 4467US2017166659A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationOMEROS CORP·Filed 2016·Application pending·0 cites
- 4566US2023265215A1Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereofOMEROS CORP·Filed 2022·Application pending·0 cites
- 4666US2015239985A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationOMEROS CORP·Filed 2014·Application pending·0 cites
- 4766US2021355236A1Methods for inhibiting fibrosis in a subject in need thereofUNIV LEICESTER·Filed 2021·Application pending·0 cites
- 4866US2019127484A1Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Various Diseases and DisordersOMEROS CORP·Filed 2018·Application pending·0 cites
- 4966US2019292272A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationOMEROS CORP·Filed 2018·Application pending·0 cites
- 5065US2020140570A1Compositions and Methods of Inhibiting MASP-2 for the Treatment of Various Thrombotic Diseases and DisordersOMEROS CORP·Filed 2019·Application pending·0 cites
Showing the top 50 of 64 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Thomas Dudler files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →